Discussions about the threat of cybercrime typically invoke images of armies of hackers whose sole task is to steal data from corporations based across the globe. Yet, as GlaxoSmithKline is now finding out, when solid allegations of cyber-espionage surface a more mundane image of an insider armed with just an email account and a thumb drive emerges.
GlaxoSmithKline has abandoned its plot to win FDA approval for an eczema treatment from Basilea Pharmaceutica, ending a project that could have paid its partner about $72 million plus royalties.
Chipmaker Qualcomm is reportedly talking to GlaxoSmithKline about setting up a $1 billion joint venture. The deal, reports of which were posted by two financial publications, would mark a continuation of Qualcomm's drive to tighten its ties to biopharma, which was given impetus last year when it set up a VC fund with Novartis and inked a deal with Roche.
The U.K.'s Competition and Markets Authority (CMA) is planning to levy "substantial fines" this year, marking a "big step up in the scale and impact" of its enforcement activity, Alex Chisholm, head of the agency, told The Financial Times. And one of those fines will likely be directed at a pharma company, Chisholm said, as the CMA probes drugmakers including GlaxoSmithKline and Pfizer for alleged wrongdoing.
Lately, GlaxoSmithKline CEO Andrew Witty has seemed open to splitting off the industry-leading consumer health joint venture he formed with Novartis last year. But let Witty be clear: It likely won't happen for a while.
Yu Xue had a hard-earned reputation as a top chemist while she was working for GlaxoSmithKline in its Upper Merion, PA, facility. But Yu Xue--better known as Joyce--was also an accomplished thief during the last four years of her 10-year tenure, according to allegations laid out in a federal indictment filed by the U.S. Attorney's office in Eastern Pennsylvania.
GlaxoSmithKline and Qualcomm are in talks to create a joint venture to enable GSK to expand into med tech, according to a report by Bloomberg that cites anonymous people knowledgeable of the matter.
Big Pharma companies--GlaxoSmithKline included--have been looking for ways to move "beyond the pill" to gain a technological leg up on their rivals. And now, the British drugmaker is reportedly weighing a move that could help it do just that.
Sanofi Pasteur has become the latest industry player to join up with the Human Vaccines Project--a global consortium seeking to address prominent issues hindering vaccine development--announcing late last week it's contributing funds for scientific and administrative activities.
In 2009, GlaxoSmithKline worked with U.S. health authorities to bring its Haemophilus influenzae Type b (Hib) vaccine, Hiberix, to market. Now, the FDA has expanded the indication of GSK's Hiberix from a booster to a full-series, four-dose vaccine to immunize children aged 6 weeks to four years.